Mestag was founded in 2020 to develop new medicines for people affected by inflammatory disease and cancer. The company develops impactful therapies for patients by targeting activated fibroblast populations and determining their role in influencing the immune system in disease. Mestag’s founding investigators comprise leading experts in inflammatory disease, cancer, computational biology and fibroblast biology united in a common vision of the role of fibroblasts in disease: Professor Michael Brenner (Brigham and Women’s Hospital & Harvard Medical School), Professor Chris Buckley (Oxford Kennedy Institute, University of Oxford), Professor David Tuveson (Cold Spring Harbor Laboratory and President of AACR), Professor Soumya Raychaudhuri (Harvard Medical School & Broad Institute) and Professor Mark Coles (Oxford Kennedy Institute, University of Oxford).
The Mestag team is progressing a pipeline of first in class therapeutics to interrupt fibroblast-mediated effects on immune cells in inflammatory disease and immuno-oncology. Mestag is headquartered in Cambridge, UK. For more information, visit www.mestagtx.com
Location: United Kingdom, England, Cambridge
Total raised: $34.01M
Investors 1
| Date | Name | Website |
| - | Forbion | forbion.co... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 04.08.2021 | Seed | $34.01M | Forbion |
Mentions in press and media 9
| Date | Title | Description | Source |
| 05.03.2024 | Mestag Therapeutics’ M300 Program, Designed to Conditionally... | - | globenewsw... |
| 20.02.2024 | Mestag Therapeutics Enlists Leading Cancer Biology and Immun... | Cambridge, UK, February 20, 2024 – Mestag Therapeutics (“Mestag”), a biotech company harnessing new ... | forbion.co... |
| 12.10.2023 | Mestag Therapeutics announces the appointment of expert advi... | Cambridge, UK, October 12, 2023 – Mestag Therapeutics (“Mestag”), a biotech company harnessing new i... | svhealthin... |
| 27.06.2023 | Mestag Therapeutics and VIB enter into an exclusive partners... | Cambridge, UK, and Ghent, Belgium, June 27, 2023 – Mestag Therapeutics (‘Mestag’), an immunotherapy ... | svhealthin... |
| 20.12.2022 | Mestag Therapeutics appoints Prof. Ton Logtenberg as Chair | CAMBRIDGE, England, Dec. 20, 2022 /PRNewswire/ -- Mestag Therapeutics ("Mestag"), an immun... | svhealthin... |
| 20.10.2022 | Mestag Therapeutics founding investigator Prof. David A. Tuv... | Cambridge, UK, October 20, – Mestag Therapeutics (“Mestag”), a breakthrough inflammatory disease and... | svhealthin... |
| 27.09.2021 | FIERCE BIOTECH NAMES MESTAG THERAPEUTICS AS ONE OF ITS “FIER... | Cambridge, UK, 27 September 2021 – Mestag Therapeutics (“Mestag”), a breakthrough inflammatory disea... | svhealthin... |
| 04.08.2021 | Mestag Therapeutics extends seed financing to $45 million an... | Mestag Therapeutics extends seed financing to $45 million and welcomes new investors 04-08-2021 Mest... | cambridgen... |
| 03.08.2021 | Forbion Leads €28.6million Seed Extension Financing for Mest... | Naarden, The Netherlands, 3 August 2021 – Forbion, a leading European life sciences venture capital ... | forbion.co... |